{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:01:46Z","timestamp":1777395706990,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,9,17]]},"DOI":"10.3233\/jad-181102","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T11:33:18Z","timestamp":1565955198000},"page":"623-630","source":"Crossref","is-referenced-by-count":16,"title":["Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer\u2019s Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM)"],"prefix":"10.1177","volume":"71","author":[{"given":"Agnes","family":"Pirker-Kees","sequence":"first","affiliation":[{"name":"Department of Neurology, General Hospital Hietzing with Neurological Center Rosenh\u00fcgel, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dal-Bianco","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Clinical Division of Neurogeriatrics and Division of General Neurology, Department of Neurology, Medical University Graz, Graz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-181102_ref1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","article-title":"Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study","volume":"172","author":"Peters","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-181102_ref2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","article-title":"The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"15","author":"Zhao","year":"2016","journal-title":"J Affect Disord"},{"key":"10.3233\/JAD-181102_ref3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1017\/S104161021700237X","article-title":"Relationship between the number of behavioral symptoms in dementia and caregiver distress: what is the tipping point?","volume":"30","author":"Arthur","year":"2018","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-181102_ref4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jagp.2013.03.014","article-title":"Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation\/aggression","volume":"23","author":"Zahodne","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-170657","article-title":"Caregiving and caregiver burden in dementia home-care: results from the Prospective Demetia Registry (PRODEM) of the Austrian Alzheimer Society","volume":"63","author":"Ransmayr","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-181102_ref6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer\u2019s dementia in individuals with previous depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-181102_ref7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/11599140-000000000-00000","article-title":"Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer\u2019s disease relieve caregiver burden?","volume":"29","author":"Levy","year":"2012","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-181102_ref8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/JGP.0b013e3181cc0333","article-title":"Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes","volume":"18","author":"Weintraub","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.archger.2007.07.010","article-title":"Trazodone for Alzheimer\u2019s disease: a naturalistic follow-up study","volume":"47","author":"L\u00f3pez-Pousa","year":"2008","journal-title":"Arch Gerontol Geriatr"},{"key":"10.3233\/JAD-181102_ref10","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","article-title":"Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study","volume":"22","author":"Camargos","year":"2914","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref11","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.3233\/JAD-181102_ref12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/JGP.0b013e31819b8936","article-title":"Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities","volume":"17","author":"Simoni-Wastila","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3233\/JAD-150869","article-title":"Classification of neuropsychiatric symptoms requiring antipsychotic treatment in patients with Alzheimer\u2019s disease: analysis of the CATIE-AD study","volume":"50","author":"Nagata","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-181102_ref14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/gps.3769","article-title":"The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer\u2019s disease","volume":"27","author":"Rosenberg","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jalz.2011.02.011","article-title":"Effects of Food and Drug Administration-approved medications for Alzheimer\u2019s disease on clinical progression","volume":"8","author":"Mielke","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-181102_ref16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-181102_ref17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.euroneuro.2014.10.004","article-title":"High prevalence of psychotropic drug use among persons with and without Alzheimer\u2019s disease in Finnish nationwide cohort","volume":"24","author":"Taipale","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.3233\/JAD-181102_ref18","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3233\/JAD-160238","article-title":"Evolution of the antidepressant prescribing in Alzheimer\u2019s disease and related disorders between 2010 and 2014: results from the French National Database on Alzheimer\u2019s Disease (BNA)","volume":"53","author":"David","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-181102_ref19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer\u2019s dementia in individuals with previous depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-181102_ref20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.rpsm.2016.11.003","article-title":"Trazodone utilization among the elderly in Spain. A population based study","volume":"11","author":"Mac\u00edas Saint-Gerons","year":"2018","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.3233\/JAD-181102_ref21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/gps.4757","article-title":"Reduced parahippocampal volume and psychosis symptoms in Alzheimer\u2019s disease","volume":"33","author":"McLachlan","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.neurobiolaging.2006.02.007","article-title":"Locus coeruleus neurofibrillary degeneration in aging mild cognitive impairment and early Alzheimer\u2019s disease","volume":"28","author":"Grudzien","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-181102_ref23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0197-4580(92)90073-7","article-title":"Cell loss in the nucleus raphes dorsalis in Alzheimer\u2019s disease","volume":"13","author":"Aletrino","year":"1992","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-181102_ref24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-015-0096-3","article-title":"Principles and management of neuropsychiatric symptoms in Alzheimer\u2019s dementia","volume":"7","author":"Nowrangi","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-181102_ref25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00019442-200409000-00007","article-title":"Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer\u2019s disease study (DIADS)","volume":"12","author":"Munro","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-181102_ref26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1440-1819.2007.01729.x","article-title":"Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychopathological symptoms in patients with Alzheimer\u2019s disease: preliminary findings from a naturalistic, retrospective study","volume":"61","author":"Rocca","year":"2007","journal-title":"Psychiatry Clin Neurosci"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-181102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:31Z","timestamp":1777370791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-181102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":26,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-181102","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]}}}